Table 5.
Adverse events associated with ATZ + BV treatment in all cases.
| Case Number |
Adverse Events | Pyrexia | Discontinuation | After Discontinuation |
|---|---|---|---|---|
| 1 | Liver disfunction * | No | No | |
| 2 | Fatigue, infusion reaction * | Yes | Yes | BSC |
| 3 | Fatigue, edema | No | Yes | BSC |
| 4 | Acute adrenal insufficiency *, increased TSH *, renal disfunction, fatigue | Yes | Yes | Observation |
| 5 | Fatigue, renal disfunction | No | Yes | BSC |
| 6 | Liver disfunction *, renal disfunction, stomatitis *, edema | Yes | Yes | ATZ + BV |
| 7 | Liver disfunction *, decreased TSH *, decreased appetite, fatigue | Yes | No | |
| 8 | Rash * | No | No | |
| 9 | Fatigue, proteinuria, increased TSH *, renal disfunction | No | No | |
| 10 | Diarrhea, ascites, liver disfunction *, proteinuria | Yes | Yes | MTA |
| 11 | Heart failure, proteinuria | No | Yes | MTA |
| 12 | None | No | No | |
| 13 | Rash *, increased TSH * | Yes | Yes | Observation |
| 14 | Oral mucositis *, rash *, stomatitis *, increased TSH * | No | Yes | Observation |
| 15 | Fatigue, decreased appetite, stomatitis *, palmar–plantar erythrodysesthesia * | Yes | Yes | BSC |
| 16 | Proteinuria, renal disfunction, hypertension, increased TSH * | No | Yes | Observation |
| 17 | Hemophagocytic syndrome *, liver disfunction * | Yes | Yes | MTA |
| 18 | Fatigue, decreased appetite, liver disfunction * | No | Yes | ATZ + BV |
| 19 | Rash, renal disfunction, liver disfunction * | No | No | |
| 20 | Decreased TSH * | No | No | |
| 21 | Ascites, increased TSH * | No | Yes | Observation |
| 22 | Fatigue, hypertension | Yes | No | |
| 23 | Rash *, palmar–plantar erythrodysesthesia *, increased TSH * | Yes | Yes | Observation |
| 24 | Hypertension | No | No | |
| 25 | Rash *, fatigue, decreased appetite | Yes | Yes | BSC |
| 26 | Diarrhea | No | No | |
| 27 | Oral mucositis * | Yes | Yes | Observation |
| 28 | None | No | No |
* The adverse event especially related with immune checkpoint inhibitor. BSC—best supportive care; MTA—molecular target agent; TSH—thyroid-stimulating hormone; ATZ—atezolizumab; BEV—bevacizumab.